XBiotech
XBIT
24 hedge funds and large institutions have $4.85M invested in XBiotech in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 7 closing their positions.
0.88% less ownership
Funds ownership: 5.14% → 4.26% (-0.88%)
23% less funds holding
Funds holding: 31 → 24 (-7)
41% less capital invested
Capital invested by funds: $8.18M → $4.85M (-$3.33M)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
59% less call options, than puts
Call options by funds: $107K | Put options by funds: $258K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$170K |
| 2 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$32.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.5K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$31.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$305K |
| 2 |
Charles Schwab
San Francisco,
California
|
-$227K |
| 3 |
Millennium Management
New York
|
-$177K |
| 4 |
ECM
Element Capital Management
New York
|
-$169K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$154K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$61K | -13,720 | Closed |
|
27
Goldman Sachs
New York
| – | -$52K | -11,513 | Closed |
|
28
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$8K | -1,762 | Closed |
|
|
SIC
29
Salem Investment Counselors
Winston Salem,
North Carolina
| – | -$2K | -500 | Closed |
|
XBIT Hedge Fund Activity: Q3 2018 in Review
24 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2018, worth a combined $4.85M — down 41% from $8.18M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of XBIT and 0 opened new positions — a net loss of 7 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $170K. The largest seller was Paloma Partners, cutting an estimated $305K.
- 24 institutional investors held XBiotech (XBIT) as of Q3 2018, down from 31 in Q2 2018.
- Funds reported $4.85M of XBiotech stock for Q3 2018, down 41% quarter-over-quarter.
- 0 funds opened new XBiotech positions in Q3 2018 and 7 closed out, a net change of -7 holders.
- The largest XBiotech buyer in Q3 2018 was Vanguard Group, an estimated $170K added.
- The largest XBiotech seller in Q3 2018 was Paloma Partners, an estimated $305K sold.
Based on aggregated 13F filings for Q3 2018.